S1PR1 and myeloid sarcoma: Of note, S1PR modulators, such as fingolimod (S1PR1,3,4,5 modulator) and siponimod (S1PR1,5), are approved as disease-modifying treatment in MS, and tested in clinical trials for ischemic and hemorrhagic stroke [238, 239].